Metraipolis › archive › dc_bccbad2695ea

A real-world disproportionality analysis of Tivozanib data mining of the public version of FDA adverse event reporting system — Europe PMC PMID:38939844

Source: Europe PMC (en)
Original: https://europepmc.org/article/MED/38939844
DOI: 10.3389/fphar.2024.1408135
License (as archived): solo-consultazione
Archived: 2026-10-08T05:10:48.200Z
SHA-256 of the archived text: 8110e7f2d51b2f0c03f35b7c1088863f693ede0c6dd8164253af780a09a61596
Stable URL of this page: https://metraipolis.com/documento/dc_bccbad2695ea

How to cite

A real-world disproportionality analysis of Tivozanib data mining of the public version of FDA adverse event reporting system — Europe PMC PMID:38939844 — Europe PMC (en), https://europepmc.org/article/MED/38939844 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_bccbad2695ea (Metraipolis archive dc_bccbad2695ea, sha256 8110e7f2d51b2f0c03f35b7c1088863f693ede0c6dd8164253af780a09a61596)

BibTeX

@misc{dcbccbad2695ea,
  title = {A real-world disproportionality analysis of Tivozanib data mining of the public version of FDA adverse event reporting system — Europe PMC PMID:38939844},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/38939844},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_bccbad2695ea; sha256 8110e7f2d51b2f0c03f35b7c1088863f693ede0c6dd8164253af780a09a61596},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/38939844. Agents can read the archived copy with the MCP tool read_document.